Danimer Scientific (DNMR) 10-Q 7 May 24 2024 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2024	May 07, 2024
Document Information [Line Items]
Entity Registrant Name	DANIMER SCIENTIFIC, INC.
Entity Central Index Key	0001779020
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2024
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-39280
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	84-1924518
Entity Address, Address Line One	140 Industrial Boulevard
Entity Address, City or Town	Bainbridge
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	39817
City Area Code	229
Local Phone Number	243-7075
Title of 12(b) Security	Class A Common stock, $0.0001 par value per share
Trading Symbol	DNMR
Security Exchange Name	NYSE
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		116,430,700

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 57,341	$ 59,170
Accounts receivable, net	12,233	15,227
Other receivables, net	682	652
Inventories, net	25,989	25,270
Prepaid expenses and other current assets	5,492	4,714
Contract assets, net	3,028	3,005
Total current assets	104,765	108,038
Property, plant and equipment, net	439,834	445,153
Intangible assets, net	77,169	77,790
Right-of-use assets	19,162	19,160
Leverage loans receivable	31,446	31,446
Restricted cash	14,239	14,334
Other assets	2,310	2,210
Total assets	688,925	698,131
Current liabilities:
Accounts payable	3,884	5,292
Accrued liabilities	6,484	4,726
Unearned revenue and contract liabilities	1,154	1,000
Current portion of lease liability	3,722	3,337
Current portion of long-term debt, net	787	1,368
Total current liabilities	16,031	15,723
Long-term lease liability, net	21,502	21,927
Long-term debt, net	384,229	381,436
Warrants liability	9,656	5
Other long-term liabilities	1,414	1,020
Total liabilities	432,832	420,111
Commitments and contingencies (Note 14)
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized: 114,240,921 and 102,832,103 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	12	10
Additional paid-in capital	737,465	732,131
Accumulated deficit	(481,384)	(454,121)
Total stockholders’ equity	256,093	278,020
Total liabilities and stockholders’ equity	$ 688,925	$ 698,131

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	114,240,921	102,832,103
Common Stock, Shares, Outstanding	114,240,921	102,832,103

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 10,224	$ 11,926
Costs and expenses:
Cost of revenue	16,535	18,209
Selling, general and administrative	6,869	18,699
Research and development	5,342	7,075
Loss on sale of assets	0	170
Total costs and expenses	28,746	44,153
Loss from operations	(18,522)	(32,227)
Nonoperating income (expense):
Gain (loss) on remeasurement of warrants	99	(1,116)
Interest, net	(8,838)	(3,386)
Total nonoperating expense:	(8,739)	(4,502)
Loss before income taxes	(27,261)	(36,729)
Income taxes	(2)	90
Net loss	$ (27,263)	$ (36,639)
Net loss per share:
Basic net loss per share	$ (0.26)	$ (0.36)
Diluted net loss per share	$ (0.26)	$ (0.36)
Basic - Weighted Average Number Of Shares Outstanding	103,968,384	101,896,326
Diluted - Weighted Average Number Of Shares Outstanding	103,968,384	101,896,326
Products
Revenue:
Total revenue	$ 9,955	$ 11,096
Services
Revenue:
Total revenue	$ 269	$ 830

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Total stockholders’ equity		$ 10	$ 676,250	$ (298,648)
Balance, beginning of period at Dec. 31, 2022		10	676,250	(298,648)
Stock-based compensation expense	$ 4,500		14,065
Warrants issued with Senior Secured Term Loan			510
Stock issued under stock compensation plan			129
Issuance of common stock, net of issuance costs		0	0
Shares retained for employee taxes			(61)
Net loss	(36,639)			(36,639)
Balance, end of period at Mar. 31, 2023	355,616	10	690,893	(335,287)
Total stockholders’ equity	355,616	10	690,893	(335,287)
Total stockholders’ equity	278,020	10	732,131	(454,121)
Balance, beginning of period at Dec. 31, 2023	278,020	10	732,131	(454,121)
Stock-based compensation expense	200		574
Warrants issued with Senior Secured Term Loan			0
Stock issued under stock compensation plan			118
Issuance of common stock, net of issuance costs		2	4,650
Shares retained for employee taxes			(8)
Net loss	(27,263)			(27,263)
Balance, end of period at Mar. 31, 2024	256,093	12	737,465	(481,384)
Total stockholders’ equity	$ 256,093	$ 12	$ 737,465	$ (481,384)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities
Net loss	$ (27,263)	$ (36,639)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	7,531	7,579
Amortization of debt issuance costs	2,818	828
Warrant issuance costs	867	0
Stock-based compensation	574	14,065
Inventory reserves	(345)	244
Accounts receivable reserves	283	(519)
Gain (loss) on remeasurement of warrants	(99)	1,116
Amortization of right-of-use assets and lease liability	(41)	(196)
Deferred income taxes	0	(92)
Loss on disposal of assets	0	170
Changes in operating assets and liabilities:
Accounts receivable	2,711	2,422
Other receivables	(30)	74
Inventories, net	(374)	753
Prepaid expenses and other current assets	(778)	1,039
Contract assets	(197)	(625)
Other assets	78	0
Accounts payable	(1,182)	(1,256)
Accrued liabilities	1,910	2,981
Other long-term liabilities	392	878
Unearned revenue and contract liabilities	154	1,313
Net cash used in operating activities	(12,991)	(5,865)
Cash flows from investing activities
Purchases of property, plant and equipment and intangible assets	(1,970)	(16,400)
Net cash used in investing activities	(1,970)	(16,400)
Cash flows from financing activities
Proceeds from issuance of common warrants, net of issuance costs	8,883	0
Proceeds from issuance of common stock, net of issuance costs	4,650	0
Principal payments on long-term debt	(606)	(5,494)
Proceeds from employee stock purchase plan	118	129
Employee taxes related to stock-based compensation	(8)	(61)
Proceeds from long-term debt	0	130,000
Cash paid for debt issuance costs	0	(33,035)
Net cash provided by financing activities	13,037	91,539
Net (decrease) increase in cash and cash equivalents and restricted cash	(1,924)	69,274
Cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash-beginning of period	73,504	64,401
Cash and cash equivalents and restricted cash-end of period	71,580	133,675
Supplemental cash flow information:
Cash paid for interest, net of interest capitalized	4,910	2,942
Cash paid for operating leases	$ 930	$ 929

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (27,263)	$ (36,639)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	Item 5. OTHER INFORMATION During the three month period ended March 31, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K, nor did the Company during such fiscal quarter adopt or terminate any “Rule 10b5-1 trading arrangement”.
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Note 1. Basis of Presentation Description of Business Danimer Scientific, Inc., together with its subsidiaries (“Company”, “Danimer”, “we”, “us”, or “our”), is a performance polymer company specializing in bioplastic replacements for traditional petroleum-based plastics. Our common stock is listed on the New York Stock Exchange under the symbol “DNMR”. The Company (formerly Live Oak Acquisition Corp. (“Live Oak”)), was incorporated in the State of Delaware on May 24, 2019 as a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses. Live Oak completed its initial public offering in May 2020. On December 29, 2020 (“Closing Date”), Live Oak consummated a business combination (“Business Combination”) with Meredian Holdings Group, Inc. (“MHG” or “Legacy Danimer”), with Legacy Danimer surviving the merger as a wholly owned subsidiary of Live Oak. The Business Combination was accounted for as a reverse recapitalization, meaning that Legacy Danimer was treated as the accounting acquirer and Live Oak was treated as the accounting acquiree. Effectively, the Business Combination was treated as the equivalent of Legacy Danimer issuing stock for the net assets of Live Oak, accompanied by a recapitalization. In connection with the Business Combination, Live Oak changed its name to Danimer Scientific, Inc. On August 11, 2021, we closed the acquisition of Novomer, Inc. (integrated into our business as “Danimer Catalytic Technologies”). Financial Statements The accompanying condensed consolidated financial statements (“financial statements”) have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and footnotes required by accounting principles generally accepted in the United States (“GAAP”) for complete financial statements. The financials statements consolidated all assets and liabilities of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. We have made certain reclassifications to previously reported amounts to conform to the current presentation. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Results of operations for interim periods are not necessarily indicative of results for the entire year. As a result, these financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K as of December 31, 2023 (“2023 Form 10-K”). We do not have any material items of other comprehensive income (loss); accordingly, there is no difference between net loss and comprehensive loss and we have not presented a separate Statement of Comprehensive Income (Loss) that would otherwise be required. There were no significant changes to our critical accounting estimates or our significant accounting policies as disclosed in our 2023 Form 10-K . Risks and Uncertainties Preparation of these financial statements is on a going concern basis of presentation according to GAAP, which assumes that we will continue our operations for the foreseeable future and be able to realize our assets and discharge our liabilities and commitments in the normal course of business. Historically, we have financed our operations through issuance of equity and debt financings, such as our senior secured term loan, convertible notes, and new market tax credit transactions described in Note 9. These financings have been used to fund working capital, capital expenditures, and our day-to-day operations. Based on our current plans and projections, we believe our unrestricted cash resources of $ 57.3 million at March 31, 2024, will be sufficient to satisfy our liquidity requirements for more than one year from when these financial statements were issued. Our ability to generate revenues in the near-term is highly dependent on the successful commercialization of our biopolymer products, which is subject to certain risks and uncertainties. As the market for our products expands, we anticipate that it will take time for our PHA production to ramp-up to an economical scale sufficient to fund our operations. As a result, we have experienced significant losses and negative cash flows in recent years and this may continue in the near term, as we incur costs and expenses for the continued development and expansion of our business, including the costs of enhancing manufacturing capacity and ongoing product research and development. The amounts we spend will impact our ability to become profitable and this spending will depend, in part, on the number of new products that we attempt to develop. Our long-term success is largely based on our PHA based resin go-to-market strategy and the effective development of alternative biodegradable resin products to support a variety of end-use cases. We are in discussions with large restaurant chains and consumer goods companies and their converters to expand the use of our PHA-based resins in straws, single-use food packaging, and utensils. Customer trends and government regulations are moving toward non-petroleum-based plastics; however, due to recent economic conditions, including the COVID-19 pandemic and supplemental supply chain disruptions, decreased Eastern European demand due to the conflict in Ukraine, and rising inflation, projected sales growth has shifted into later periods. As a result of these developments, we have taken actions to reduce our operating costs across all areas of the business and to more closely monitor our liquidity position. For example, we have reduced discretionary spending, reduced labor costs through employee headcount rationalization, increased focus by senior management on collections of accounts receivable, postponed certain capital expenditures, and launched an initiative to reduce on-hand inventory levels to respond to the business environment.

Inventories, net

Inventories, net	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Inventories	Note 2. Inventories, net Inventories, net consisted of the following: March 31, December 31, (in thousands) 2024 2023 Raw materials $ 11,843 $ 10,867 Work in process 503 546 Finished goods and related items 13,643 13,857 Total inventories, net $ 25,989 $ 25,270 At March 31, 2024 and December 31, 2023, finished goods and related items included $ 8.1 million and $ 7.6 million, respectively, of finished neat PHA. Inventory at March 31, 2024 is stated net of reserves of $ 0.6 million related to interim assessments to reduce the carrying value of inventory to its net realizable value.

Property, Plant and Equipment,

Property, Plant and Equipment, net	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, net	Note 3. Property, Plant and Equipment, net Property, plant and equipment, net, consisted of the following: March 31, December 31, (in thousands) Estimated Useful Life (Years) 2024 2023 Land and improvements 20 $ 92 $ 92 Leasehold improvements Shorter of useful life or lease term 110,540 110,531 Buildings 20 - 40 2,191 2,191 Machinery and equipment 3 - 20 190,556 190,111 Motor vehicles 7 - 10 903 903 Furniture and fixtures 3 - 10 474 474 Office equipment 3 - 10 7,422 7,415 Construction in progress N/A 203,617 202,998 515,795 514,715 Accumulated depreciation and amortization ( 75,961 ) ( 69,562 ) Property, plant and equipment, net $ 439,834 $ 445,153 We reported depreciation and amortization expense (which included amortization of intangible assets) as follows: Years Ended March 31, (in thousands) 2024 2023 Cost of revenue $ 5,147 $ 5,213 Research and development 2,031 2,082 Selling, general and administrative 353 284 Total depreciation and amortization expense $ 7,531 $ 7,579 Construction in progress consists primarily of the early phases of construction of our PHA plant in Bainbridge, Georgia (“Greenfield Facility”) as noted in the table below. We do not have expected in-service dates for our Greenfield Facility, since we have paused major construction. We will need to obtain additional financing to complete our Greenfield Facility. In 2022, the engineering cost estimate ranged from $ 515 million to $ 665 million, which does not consider any effect of subsequent inflation, and if we do not obtain financing, our investment could be impaired. (in thousands) March 31, December 31, Georgia $ 200,047 $ 199,342 New York 1,827 1,960 Kentucky 1,743 1,696 $ 203,617 $ 202,998 Property, plant and equipment includes gross capitalized interest of $ 15.0 million as of both March 31, 2024 and December 31, 2023. For the three months ended March 31, 2024 and 2023, capitalized interest costs were immaterial.

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 4. Intangible Assets Our recognized intangible assets consist of patents and the unpatented technological know-how of Danimer Catalytic Technologies. Our legacy patents were initially recorded at cost. The values of Danimer Catalytic Technologies’ patents and unpatented know-how are inseparable and represent their acquisition-date fair value, less subsequent amortization. We capitalize patent defense and application costs and amortize these costs on a straight-line basis over their estimated useful lives, which range from 10 to 20 years. Our intangible portfolio has an estimated weighted average useful life of 17.3 years. Intangible assets, net, consisted of the following: March 31, December 31, (in thousands) 2024 2023 Intangible assets, gross $ 96,276 $ 95,765 Less capitalized patent costs not yet subject to amortization ( 3,102 ) ( 2,838 ) Intangible assets subject to amortization, gross 93,174 92,927 Accumulated amortization ( 19,107 ) ( 17,975 ) Intangible assets subject to amortization, net 74,067 74,952 Total intangible assets, net $ 77,169 $ 77,790 Amortization expense was $ 1.1 million d uring each of the three months ended March 31, 2024 and 2023 and was included in research and development costs.

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2024
Accounts Payable and Accrued Liabilities [Abstract]
Accrued Liabilities	Note 5. Accrued Liabilities The components of accrued liabilities were as follows: March 31, December 31, (in thousands) 2024 2023 Accrued interest $ 2,399 $ 440 Accrued legal, consulting and professional fees 1,408 839 Accrued taxes 912 552 Compensation and related expenses 508 1,692 Accrued utilities 341 350 Accrued rebates 288 233 Construction in progress accruals 51 191 Purchase accrual - 8 Other 577 421 Total accrued liabilities $ 6,484 $ 4,726

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 6. Income Taxes We reported immaterial income tax expense for the three months ended March 31, 2024, which resulted in an effective income tax rate of zero percent. We reported an income tax benefit for the three months ended March 31, 2023 of $ 0.1 million, which resulted in effective income tax rate of 0.25 %. Our effective tax rates differed from the federal statutory rate of 21 % due to our valuation allowances against substantially all of our net deferred income tax assets. In assessing the realizability of deferred income tax assets, we consider whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods at which time those temporary differences become deductible. In making valuation allowance determinations, we consider all available evidence, positive and negative, affecting specific deferred income tax assets, including the scheduled reversal of deferred income tax liabilities, projected future taxable income, the length of carry-back and carry-forward periods, and tax planning strategies in making this assessment. At March 31, 2024, we maintained a partial valuation allowance against our net deferred income tax assets due to the uncertainty surrounding realization of such assets.

Leases

Leases	3 Months Ended
	Mar. 31, 2024
Disclosure Text Block [Abstract]
Operating Leases	Note 7. Leases The following table sets forth the allocation of our operating lease costs. Three Months Ended March 31, (in thousands) 2024 2023 Cost of revenue $ 754 $ 581 Selling, general and administrative 33 137 Research and development 248 76 Total operating lease cost $ 1,035 $ 794

Warrant Liability

Warrant Liability	3 Months Ended
	Mar. 31, 2024
Text Block [Abstract]
Warrant Liability	Note 8. Warrant Liability Private Warrants At March 31, 2024 and December 31, 2023, there were 3,914,525 outstanding warrants to purchase shares of our common stock at an exercise price of $ 11.50 per share, subject to adjustments, which were privately placed prior to the Business Combination (“Private Warrants” ). The Private Warrants have been exercisable since May 7, 2021 . On December 28, 2025 , any outstanding Private Warrants will expire. The Private Warrants meet the definition of derivative instruments and are reported as liabilities at their fair values at each period end, with changes in the fair value of the Private Warrants recorded as a non-cash loss or gain. A rollforward of the Private Warrants liability is below. (in thousands) Balance at December 31, 2023 $ ( 5 ) Loss on remeasurement of private warrants ( 201 ) Balance at March 31, 2024 $ ( 206 ) Common Warrants On March 25, 2024, we closed a registered direct offering of our common stock that included accompanying warrants to purchase up to an aggregate of 15,000,000 shares of Common Stock (“Common Warrants”). The Common Warrants have an exercise price of $ 1.33 per share, are exercisable beginning on September 25, 2024 , and expire on September 25, 2029 . The Common Warrants meet the definition of derivative instruments and are reported as liabilities at their fair values at each period end, with changes in the fair value of the Common Warrants recorded as a non-cash loss or gain. A rollforward of the Common Warrants liability is below. (in thousands) Balance at March 25, 2024 $ ( 9,750 ) Gain on remeasurement of common warrants 300 Balance at March 31, 2024 $ ( 9,450 )

Debt

Debt	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Long-Term Debt	Note 9. Debt The components of long-term debt were as follows: March 31, December 31, (in thousands) 2024 2023 3.25 % Convertible Senior Notes $ 240,000 $ 240,000 Senior Secured Term Loan 130,000 130,000 New Market Tax Credit Transactions 45,700 45,700 Insurance Premium Finance Notes 671 1,243 Vehicle and Equipment Notes 296 327 Mortgage Notes 189 192 Total $ 416,856 $ 417,462 Less: Total unamortized debt issuance costs ( 31,840 ) ( 34,658 ) Less: Current maturities of long-term debt ( 787 ) ( 1,368 ) Total long-term debt $ 384,229 $ 381,436 3.25% Convertible Senior Notes On December 21, 2021, we issued $ $ 240 million principal amount of our 3.25 % Convertible Senior Notes due 2026 (“Convertible Notes”), subject to an indenture. The Convertible Notes are our senior, unsecured obligations and accrue interest at a rate of 3.25 % per annum, payable semi-annually in arrears on June 15 and December 15 of each year, beginning on June 15, 2022. We will settle conversions by paying or delivering, as applicable, cash, shares of common stock or a combination of cash and shares, at our election. The initial conversion rate, which is subject to change, is approximately $ 10.79 per share of common stock. If certain liquidity conditions are met, we may redeem the Convertible Notes between December 19, 2024 and October 20, 2026. The Convertible Notes mature on December 15, 2026. Capped Calls Also in December 2021, in connection with the Convertible Notes, we purchased call options (“Capped Calls”) from certain well-capitalized financial institutions for $ 35 million. The Capped Calls permit us to require the counterparties to deliver to us shares of our common stock, subject to a capped number of shares. We may also net-settle the Capped Calls and receive cash instead of shares. We have not exercised any of the Capped Calls at March 31, 2024, and the Capped Calls expire on April 12, 2027 . Senior Secured Term Loan On March 17, 2023, we closed a $ 130 million principal amount senior secured term loan (“Senior Secured Term Loan”). The Senior Secured Term Loan is secured by substantially all of our assets, other than the assets of Danimer Catalytic Technologies and assets associated with the Greenfield Facility. The Senior Secured Term Loan matures on the earlier of March 17, 2027 or September 15, 2026 if more than $ 100 million of the existing Convertible Notes remain outstanding on that date. After payment of the lender’s expenses, including the first three years of premiums for a collateral protection insurance policy for the benefit of the lender, we received net proceeds of $ 98.6 million. The Senior Secured Term Loan accrues interest at a stated annual rate of 14.4 % , payable monthly. As part of the Senior Secured Term Loan agreement, we are required to hold $ 12.5 million in an interest-payment reserve account, which we have reported as restricted cash. The Senior Secured Term Loan contains various customary covenants, which we do not expect to have a material impact on our liquidity or capital resources. In connection with the Senior Secured Term Loan, we also issued warrants with a five-year maturity to the lender to purchase 1.5 million shares of our common stock at an exercise price of $ 7.50 per share. We determined the fair value of these warrants as of the closing date was $ 0.5 million using the Black-Scholes model and included this amount in additional paid-in capital. New Markets Tax Credit Transactions We entered into financing arrangements under the New Markets Tax Credit (“NMTC”) program with various unrelated third-party financial institutions (individually and collectively referred to as “Investors”), which then invest in certain “Investment Funds”. In each of the financing arrangements, we loaned money to the Investment Funds. These loans of $ 31.4 million are recorded as leveraged loan receivables as of March 31, 2024 and December 31, 2023, respectively. Each Investment Fund then contributed the funds from our loan and the Investor’s investment to a special purpose entity, which then in turn loaned the contributed funds to a wholly owned subsidiary of the Company. We believe these borrowings, and our related loans to the Investment Funds, will be forgiven in 2026 and 2029. Insurance Premium Finance Notes In June 2023 and December 2023, we entered into financing agreements related to the premiums of certain insurance policies. Each of these notes have a one year term and bear interest at 8.24 % . Vehicle and Equipment Notes We have thirteen vehicle and equipment notes outstanding at March 31, 2024, primarily relating to motor vehicles and warehouse equipment. We make monthly payments on these notes at interest rates ranging from 3.75 % to 6.99 % . Mortgage Notes We have a mortgage note secured by a residential property. This note bears interest at 5.25 % with a maturity date in May 2025.

Equity

Equity	3 Months Ended
	Mar. 31, 2024
Stockholders' Equity Note [Abstract]
Equity	Note 10. Equity Common Stock The following table summarizes the common stock activity for the three months ended March 31, 2024 and 2023, respectively. Three Months Ended March 31, 2024 2023 Balance, beginning of period 102,832,103 101,804,454 Issuance of common stock 11,408,818 133,922 Balance, end of period 114,240,921 101,938,376 Preferred Stock We are authorized to issue up to 10,000,000 shares of preferred stock, each with a par value of $ 0.0001 per share. As of March 31, 2024 and December 31, 2023, no shares of preferred stock were issued or outstanding. Non-Plan Legacy Danimer Options Prior to 2017, Legacy Danimer had issued 208,183 stock options that were not a part of either the 2016 Executive Plan or the 2016 Omnibus Plan. These options had a weighted average exercise price of $ 30 per share. On December 29, 2020, the then-remaining 30,493 of these options were converted to options to purchase 279,255 shares of our common stock with a weighted average exercise price of $ 3.28 per share. During 2021, 153,763 of these options were exercised. There were 125,492 of these options remaining outstanding at March 31, 2024 and December 31, 2023. Equity Distribution Agreement On September 7, 2022, we entered into an equity distribution agreement with Citigroup Global Markets Inc. (“Manager”), under which we may issue and sell shares of our common stock “at the market” from time-to-time with an aggregate offering price of up to $ 100.0 million (“ATM Offering”). Under the ATM Offering, the Manager may sell small volumes of our common stock at the prevailing market price, during such times and on such terms as we have predesignated. We have no obligation to sell any shares and may at any time suspend offers and sales that are part of the ATM Offering and may terminate the ATM Offering without penalty. On a life-to-date basis, we have issued 590,661 shares at an average price of $ 2.72 resulting in proceeds of $ 1.4 million. We incurred life-to-date issuance costs of $ 1.4 million, which were primarily one-time costs, but which also included less than $ 0.1 million in commissions to the Manager. On March 20, 2024, we amended the prospectus supplement relating to the ATM Offering to reduce the amount available for sale pursuant to the agreement from $ 100.0 million to $ 50.0 million. As of March 31, 2024, $ 48.6 million remains available for distribution under the ATM Offering. Anti-dilutive Instruments The following table summarizes the instruments excluded from the calculations of diluted shares outstanding because the effect of including them would have been anti-dilutive. Three Months Ended March 31,  2024  2023 Convertible Notes 22,250,040  22,250,040 Common Warrants 15,000,000 - Employee stock options 9,253,370  12,044,231 Private Warrants 3,914,525  3,914,525 Pre-Funded Warrants 3,750,000 - Senior Secured Term Loan Warrants 1,500,000 1,500,000 Restricted stock and RSUs 1,316,383 2,142,515 Performance stock 127,770 127,770 Legacy Danimer options 125,492  125,492 Total excluded instruments 57,237,580 42,104,573 Senior Secured Term Loan Warrants On March 17, 2023, we issued warrants to purchase 1.5 million shares of our common stock for $ 7.50 per share in connection with the closing of the Senior Secured Term Loan. These warrants were accounted for as an equity arrangement and were included in additional paid-in-capital at March 31, 2024 and 2023. Pre-Funded Warrants On March 25, 2024, we completed a registered direct offering for the purchase and sale of an aggregate of 11,250,000 shares of our common stock, as well as pre-funded warrants to purchase up to an aggregate of 3,750,000 shares of our common stock (“Pre-Funded Warrants”) resulting in gross proceeds of approximately $ 15.0 million less customary closing fees. The Pre-Funded Warrants have an exercise price of $ 0.0001 per share and expire on March 26, 2029 . The Pre-Funded Warrants were accounted for as an equity arrangement and were included in additional paid-in-capital at March 31, 2024. We also determined that the Pre-Funded Warrants should be included in the determination of basic earnings per share in accordance with ASC 260, Earnings per Share .

Revenue

Revenue	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenue	Note 11. Revenue We evaluate financial performance and make resource allocation decisions based upon the results of our single operating and reportable segment; however, we believe presenting revenue split between our primary revenue streams of products and services best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors. We generally produce and sell finished products, for which we recognize revenue upon shipment. We provide for expected returns based on historical experience and future outlook. Variable consideration such as discounts, rebates, or volume discounts that we estimate to reduce our transaction price are not material. We defer certain contract fulfillment costs and amortize these costs to cost of revenue on a per-pound basis as we sell the related product or when the related contracts expire. During the three months ended March 31, 2024 and 2023, amortization of these contract fulfillment costs was immaterial. At each of March 31, 2024 and December 31, 2023, we had gross contract fulfillment costs of $ 1.3 million and net contract fulfillment costs of $ 1.1 million, which were included in other assets. Our research and development (“R&D”) services contract customers generally pay us at the commencement of the agreement and then at additional intervals as outlined in each contract. We recognize contract liabilities for such payments and then recognize revenue as we satisfy the related performance obligations. To the extent collectible revenue recognized under this method exceeds the consideration received, we recognize contract assets for such unbilled consideration. R&D contract assets, net were $ 3.9 million and $ 3.7 million at March 31, 2024 and December 31, 2023, respectively. The long term portion of these assets were $ 0.9 million and $ 0.7 million at March 31, 2024 and December 31, 2023, respectively and are included in other assets. Revenue recognized that was included in contract liabilities at the beginning of the period was not material for any period presented. Disaggregated Revenues Revenue by geographic areas is based on the location of the customer. The following table summarizes revenue information by major geographic area. Three Months Ended March 31, (in thousands) 2024 2023 Domestic $ 9,729 $ 10,274 Portugal 180 - Poland 155 77 Switzerland 91 - All other countries 69 1,575 Total revenues $ 10,224 $ 11,926

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	Note 12. Stock-Based Compensation We grant various forms of stock-based compensation, including restricted stock, restricted stock units, stock options and performance-based restricted stock units under our Danimer Scientific, Inc. 2020 Long-Term Equity Incentive Plan (“2020 Incentive Plan”) and employee stock purchase plan instruments under our 2020 Employee Stock Purchase Plan (“2020 ESPP Plan”). We also have outstanding employee and director stock options that were issued prior to the Business Combination under legacy stock plans. The 2020 Incentive Plan provides for the grant of stock options, stock appreciation rights, and full value awards. Full value awards include restricted stock, restricted stock units, deferred stock units, performance stock and performance stock units. On March 31, 2024 and December 31, 2023, 4,519,719 shares and 4,823,519 shares, respectively, of our common stock remained authorized for issuance with respect to awards under the 2020 Incentive Plan. The 2020 ESPP Plan provides for the sale of our common stock to our employees through payroll withholding at a discount of 15 % from the lower of the closing price of our common stock on the first or last day of each biannual offering period. Up to 2,571,737 shares of our common stock were authorized to be issued under this plan, and we issued 136,530 shares during the three months ended March 31, 2024 resulting in 401,748 shares issued since the inception of the plan. These share pool limits are subject to adjustment in the event of a stock split, stock dividend or other changes in our capitalization. The following table sets forth the allocation of our stock-based compensation expense. Three Months Ended March 31, (in thousands) 2024 2023 Cost of revenue $ 3 $ 2 Selling, general and administrative 818 13,318 Research and development 145 1,623 Total stock-based compensation $ 966 $ 14,943 Service-based Restricted Stock and RSUs The following table summarizes our service-based restricted stock and RSU activity under our equity plan.   Number of Shares  Weighted Average Grant-Date Balance, December 31, 2023  271,550  $ 4.40 Granted 315,876 $ 1.49 Vested ( 34,364 ) $ 5.86 Balance, March 31, 2024 553,062 $ 1.82 We recognize the compensation expense for these shares on a straight-line basis from the grant date through the relevant vesting dates, which range from one to three years. We recognized $ 0.2 million and $ 4.5 million o f expense related to these awards during the three months ended March 31, 2024 and 2023, respectively. Market-based Restricted Stock During 2021, we granted 1,517,840 shares of restricted stock for which the restrictions lapse on successive thirds of the award on the first date the volume-weighted average price per share of our common stock equals or exceeds $ 24.20 for any 20 trading dates within 30-day trading periods beginning on December 29, 2021, 2022, and 2023, respectively. These awards were fully amortized at December 31, 2023. We recognized $ 4.7 million of related expense during the three months ended March 31, 2023. During 2023, we instituted a cash settlement feature for certain of these awards if the 2020 Incentive Plan does not have enough shares remaining to fulfill these awards at the time of vesting. As such, 754,818 of the 1,517,840 shares of market-based restricted stock are accounted for as liabilities that are marked to market each period. We maintained a liability of $ 0.3 million as a result of this feature as of March 31, 2024 and December 31, 2023. All of these shares remained outstanding at March 31, 2024. Performance-based Restricted Stock Units During 2021, we initiated a Performance-based RSU program. Under this program, each participant is awarded a number of units (“PRSU”s) that may vest based on our performance against one or more specified metrics, with 50 % to 100 % of these PRSUs vesting proportionally with achieved threshold and target attainment levels. In some cases, these PRSUs contain a cash settlement feature and we accounted for these PRSUs as liabilities that are marked to market using the price of our common stock at the end of each reporting period with a life-to-date expense adjustment. As of March 31, 2024, we maintain a long-term liability for PRSUs of $ 0.1 million. For the three months ended March 31, 2024 and 2023, respectively, we recognized related compensation expense of zero and $ 0.3 million , which we included in selling, general and administrative expenses. Other than the mark to market effect, expense is recognized on a straight-line basis between the dates of grant and the vesting dates, which we anticipate will be in March 2025 and February 2026, for awards granted in 2022 and 2023, respectively. Our performance did not meet the required conditions for vesting for the PRSUs that were scheduled to vest in February 2024 and accordingly they expired unvested during the three months ended March 31, 2024. We are currently assuming 100% attainment of our 2025 metrics and 0% attainment of our 2024 metrics. All of the PRSUs granted in 2022 and 2023 remained outstanding at March 31, 2024. The following table summarizes pertinent facts related to PRSU grants, with threshold and target dollar and production capacity figures given in millions. Grant Date Grant-Date Fair Value # Cash-Settleable PRSUs # Share-Settleable PRSUs Metric Threshold Target 2/28/2023 $ 2.58 192,500 38,759 2025 PHA Revenue $ 177.0 $ 202.0 2/28/2023 $ 2.58 192,500 38,760 2025 Adjusted EBITDA $ 36.0 $ 44.0 3/31/2022 $ 5.86 131,909 15,075 2024 PHA Revenue $ 151.0 $ 189.0 3/31/2022 $ 5.86 131,909 15,075 2024 Adjusted EBITDA $ 9.2 $ 13.8 3/31/2022 $ 5.86 175,880 20,101 2024 Neat PHA capacity (lbs.) 68.0 81.0 824,698 127,770 Stock Options The following table summarizes share-settled stock option activity under our equity plans.   Number of Options  Weighted Average Exercise Price  Weighted Average Remaining Contractual Term (Years)  Aggregate Intrinsic Value Balance, December 31, 2023  9,257,704 $ 11.27 5.38 $ - Forfeited ( 4,334 ) Balance, March 31, 2024 9,253,370 $ 11.27 5.13 $ - Exercisable  8,118,263 $ 12.10 4.77 $ - Vested and expected to vest  9,253,370 $ 11.27 5.13 $ - The aggregate intrinsic values are calculated as the difference between the exercise price of the indicated stock options and the fair value of our common stock on March 31, 2024. There were no stock options granted during the three months ended March 31, 2024. There were 204,254 share-settled options granted during the three months ended March 31, 2023 with a weighted average grant date fair value of $ 1.17 . In addition to the share-settled stock options, during the three months ended March 31, 2023, we granted 1,050,000 stock options that contained a cash-settlement feature if adequate shares were not available to settle the award by the vesting dates. Additionally, during 2023, we added a cash-settlement feature to 2,571,737 of previously outstanding share-settled stock options and we maintain a liability of $ 0.4 million as of March 31, 2024 for these options, which was reclassified from additional paid-in capital. For the three months ended March 31, 2024 and 2023, we recognized expense of $ 0.4 million and $ 0.6 million, respectively for all outstanding cash-settleable stock options. We maintained long-term liabilities of $ 0.5 million and $ 0.1 million at March 31, 2024 and December 31, 2023, respectively, related to our historical outstanding cash-settleable stock options. As of March 31, 2024, there was $ 2.7 million of unrecognized compensation cost related to unvested stock options and restricted shares granted under the 2020 Incentive Plan. That cost is expected to be recognized over a weighted-average period of 0.9 years.

Fair Value Considerations

Fair Value Considerations	3 Months Ended
	Mar. 31, 2024
Fair Value Considerations [Abstract]
Fair Value Considerations	Note 13. Fair Value Considerations GAAP defines “fair value” as the price we would receive to sell an asset in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer. GAAP also sets forth a framework for measuring fair value utilizing a three-tier hierarchy based on the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of the fair value hierarchy are as follows: Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities; Level 2 - Observable inputs other than quoted prices in active markets, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data; and Level 3 - Unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. Level 1 The carrying amounts of our cash and cash equivalents and restricted cash were measured using quoted market prices in active markets and represent Level 1 investments. Our other financial instruments such as accounts receivable, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The March 31, 2024 fair value of our Convertible Notes, based on trades made around that date, was approximately $ 17.8 million. We set the values of our restricted stock unit and restricted stock awards without market-based vesting provisions on their respective grant dates at the closing price of a share of our common stock on each grant date. We re-value our restricted stock unit awards that include a cash settlement feature each month at the closing price of a share of our common stock on the last trading day of the month, or $ 1.09 at March 31, 2024. Level 2 We valued our restricted stock awards that contain a market-based vesting provision on the grant date using a Monte Carlo simulation, which takes into account a large number of potential stock price scenarios over time and incorporates varied assumptions about volatility and exercise behavior for those various scenarios. These assumptions are based on market data but cannot be directly observed. A fair value is estimated for each potential outcome. We estimated the fair value of our Senior Secured Term Loan based on an analysis of market activity since loan inception at March 31, 2024 and determined it was approximately $ 40.5 million. Level 3 We value our stock options, ESPP instruments, Private Warrants and Common Warrants using the Black-Scholes option pricing model on the respective grant dates. We re-value the Private Warrants, Common Warrants and any stock options with a cash-settlement feature at the end of each period. Since our stock price history as a publicly traded company is shorter in duration than the expected lives of our options (other than ESPP instruments), we use the historical volatility of a group of peer companies in addition to our own historical volatility to assess expected volatility. We have not paid and do not currently anticipate paying a cash dividend on our common stock, so we have set the expected annual dividend yield to zero for all calculations. We used risk-free rates equal to the U.S. Treasury yield curves in effect as of each valuation date for durations equal to the expected lives of each instrument. We use the simplified method under Staff Accounting Bulletin Topic 14, defined as the mid-point between the vesting period and the contractual term for each option, to determine the expected lives of stock-settled stock options and we use the remaining contractual lives of ESPP instruments, Private Warrants, Common Warrants, and stock options with a cash-settlement feature as their expected lives. The following table sets forth the calculated fair values and the associated ranges of values we used for period remeasurement and for new grants in our Black-Scholes calculations for stock options, other than ESPP. March 31, Three Months Ended March 31, 2024 2024 2023 Share prices of our common stock $ 1.09 $ 1.09 $ 2.58 - $ 3.45 Expected volatilities 79.78 % 65.28 % - 100.92 % 49.08 % - 53.51 % Risk-free rates of return 4.21 % 4.13 % - 4.28 % 4.04 % - 4.40 % Expected option terms (years) 4.08 3.31 - 4.91 4.31 - 6.00 Calculated option values $ 0.23 $ 0.15 - $ 0.41 $ 0.20 - $ 2.04 The following table sets forth the fair values we calculated and the inputs we used in our Black-Scholes models for Private Warrants. March 31, December 31, 2024 2023 Share price of our common stock $ 1.09 $ 1.02 Expected volatility 95.80 % 56.66 % Risk-free rate of return 4.68 % 4.31 % Expected warrant term (years) 1.74 2.00 Fair value determined per warrant $ 0.05 $ 0.00 The following table sets forth the fair values we calculated and the inputs we used in our Black-Scholes models for Common Warrants. March 31, March 25, 2024 2024 Share price of our common stock $ 1.09 $ 1.08 Expected volatility 68.42 % 72.80 % Risk-free rate of return 4.12 % 4.15 % Expected warrant term (years) 5.49 5.50 Fair value determined per warrant $ 0.63 $ 0.65

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14. Commitments and Contingencies Commitments In connection with our 2007 acquisition of certain intellectual property, we agreed to pay royalties to Procter & Gamble upon production and sale of PHA. The royalty is $ 0.05 per pound for the first 500 million pounds of PHA sold and decreases to $ 0.025 per pound for cumulative sales in excess of that amount until the underlying patents expire. On March 17, 2023, we terminated this royalty agreement. We retained all intellectual property associated with the agreement. We forfeited all prepaid royalties as part of this termination and recorded a loss on forfeiture of $ 0.5 million for the three months ended March 31, 2023. Litigation Matters On May 14, 2021, a class action complaint was filed by Darryl Keith Rosencrants in the United States District Court for the Eastern District of New York, on May 18, 2021, a class action complaint was filed by Carlos Caballeros in the United States District Court for the Middle District of Georgia, on May 18, 2021, a class action complaint was filed by Dennis H. Wilkins also in the United States District Court for the Middle District of Georgia, and on May 19, 2021, a class action complaint was filed by Elizabeth and John Skistimas in the United States District Court for the Eastern District of New York. Each plaintiff or plaintiffs brought the action individually and on behalf of all others similarly situated against the Company. The alleged class varies in each case but covers all persons and entities other than Defendants who purchased or otherwise acquired our securities between October 5, 2020 and May 4, 2021 (“Class Period”). Plaintiffs are seeking to recover damages caused by Defendants’ alleged violations of the federal securities laws and are pursuing remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and Rule 10b-5 promulgated thereunder. The complaints are substantially similar and are each premised upon various allegations that throughout the Class Period, Defendants made materially false and misleading statements regarding, among other things, our business, operations and compliance policies. Plaintiffs seek the following remedies: (i) determining that the lawsuits may be maintained as class actions under Rule 23 of the Federal Rules of Civil Procedure, (ii) certifying a class representative, (iii) requiring Defendants to pay damages allegedly sustained by plaintiffs and the class members by reason of the acts alleged in the complaints, and (iv) awarding pre-judgment and post-judgment interest as well as reasonable attorneys’ fees, expert fees and other costs. On July 29, 2021, the Georgia court transferred the Georgia cases to New York, and all four class actions have been consolidated into a single lawsuit in the Eastern District of New York. On January 19, 2022, a Consolidated Amended Class Action Complaint (“Amended Complaint”) was filed in the Eastern District of New York, naming as defendants the Company, its directors and certain of its officers as well as certain former directors (collectively, “Defendants”). The Amended Complaint is brought on behalf of a class consisting of (i) purchasers of shares of the Company during the Class Period, (ii) all holders of the Company’s Class A common stock entitled to vote on the merger transaction between the Company and Meredian Holdings Group, Inc. consummated on December 28, 2020 and (iii) purchasers of Company securities pursuant to the Company’s Registration Statement on Form S-4 that was declared effective on December 16, 2020 or the Company’s Registration Statement on Form S-1 that was declared effective on February 16, 2021. The Amended Complaint asserts claims for violations of Sections 10(b), 14(a) and 20(a) of the Exchange Act and Rules 10(b)-5(a)-(c) promulgated thereunder and Sections 11, 12 and 15 of the Securities Act of 1933, as amended (the “Securities Act”). Plaintiffs seek the following remedies: (a) a determination that the lawsuit is a proper class action pursuant to Rule 23 of the Federal Rules of Civil Procedure and certifying Plaintiffs as class representative, (b) awarding compensatory and punitive damages allegedly sustained by the class members by reason of the acts set forth in the Amended Complaint and (c) awarding pre-judgment and post-judgment interest and costs and expenses, including reasonable attorneys’ fees, experts’ fees and other costs. On September 30, 2023, the court issued an Order granting Defendant’s motion to dismiss in full, dismissing Plaintiffs’ claims with prejudice, and denying Plaintiffs’ request for leave to amend. On October 27, 2023, the Plaintiffs filed a notice of appeal, which remains pending. On May 24, 2021, a shareholder derivative lawsuit was filed in the Court of Chancery of the State of Delaware by Richard Delman on behalf of the Company, alleging breach of fiduciary duty against the Company’s directors. On October 6, 2021, a shareholder derivative lawsuit was filed in the United States District Court for the District of Delaware by Ryan Perri on behalf of the Company, alleging breach of fiduciary duty against the Company’s directors. On February 9, 2023, a shareholder derivative lawsuit was filed in the United States District Court for the District of Delaware by Samuel Berezin on behalf of the Company, alleging breach of fiduciary trust against the Company’s directors. All three shareholder derivative lawsuits have been stayed pending the outcome of Defendants’ motion to dismiss the securities class actions. These derivative complaints repeat certain allegations which are already in the public domain. Defendants deny the allegations of the above complaints, believe the lawsuits are without merit and intend to defend them vigorously. We provide for costs relating to these matters when a loss is probable and the amount is reasonably estimable. Since we are unable to estimate the likelihood of incurring a loss, or the amount of loss, if any, related to these matters, we have not accrued any losses for these matters at March 31, 2024. Legal and administrative costs related to these matters are expensed as incurred. On May 5, 2021, we received a letter from the Atlanta regional office of the SEC, in connection with a non-public, fact-finding inquiry, requesting that we voluntarily produce certain specified information, to which we timely and voluntarily produced the requested information on July 14, 2021. Subsequently, the SEC had additional follow-up requests for further information, and we have timely and voluntarily responded to all such requests. In the ordinary course of business, we may be a party to various other legal proceedings from time to time.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 15. Subsequent Events On April 19, 2024, we entered into an asset-based credit and security agreement (“Revolving Credit Agreement”) with Mountain Ridge Capital. The Revolving Credit Agreement provides for borrowings under a revolving commitment of $ 20.0 million (“Revolving Commitment”). Subject to the terms and conditions of the Revolving Credit Agreement, we may request an increase in the Revolving Commitment by an amount not to exceed $ 5.0 million, provided that any such request for an increase be in a minimum amount of $ 2.5 million. The amount of the Revolving Commitment available for borrowing at any given time is $ 18.5 million, subject to a borrowing base formula that is based upon our accounts receivable and inventory, as more fully described in the Revolving Credit Agreement. Amounts borrowed under the Revolving Credit Agreement accrue interest at an annual rate equal to the Secured Overnight Financing Rate plus 7 %, and any unborrowed Revolving Commitment accrues an unused facility fee at an annual rate of 0.5 %, each payable monthly . The Revolving Credit Agreement matures on April 19, 2027 ; however, certain provisions exist that can accelerate the maturity date . The Revolving Credit Agreement also contains other customary representations, warranties, and affirmative and negative covenants, which we do not expect to have any material effect. The Revolving Credit Agreement is secured by a lien on all of our accounts receivable and inventory and the proceeds thereof and certain other assets as set forth in the Revolving Credit Agreement. On May 2, 2024, we announced that our Board of Directors proposed a distribution of warrants to purchase shares of Common Stock (“Dividend Warrants”). This transaction is subject to our stockholders approving a proposal to increase the number of shares of Common Stock authorized at our upcoming annual meeting of stockholders, to be held on July 9, 2024. The Dividend Warrants would be distributed on or about July 12, 2024, to the holders of record of our Common Stock as of the close of business on May 13, 2024.

Inventories, net (Tables)

Inventories, net (Tables)	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Schedule of inventory	Inventories, net consisted of the following: March 31, December 31, (in thousands) 2024 2023 Raw materials $ 11,843 $ 10,867 Work in process 503 546 Finished goods and related items 13,643 13,857 Total inventories, net $ 25,989 $ 25,270

Property, Plant and Equipment_2

Property, Plant and Equipment, net (Tables)	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property, plant, and equipment, net	Property, plant and equipment, net, consisted of the following: March 31, December 31, (in thousands) Estimated Useful Life (Years) 2024 2023 Land and improvements 20 $ 92 $ 92 Leasehold improvements Shorter of useful life or lease term 110,540 110,531 Buildings 20 - 40 2,191 2,191 Machinery and equipment 3 - 20 190,556 190,111 Motor vehicles 7 - 10 903 903 Furniture and fixtures 3 - 10 474 474 Office equipment 3 - 10 7,422 7,415 Construction in progress N/A 203,617 202,998 515,795 514,715 Accumulated depreciation and amortization ( 75,961 ) ( 69,562 ) Property, plant and equipment, net $ 439,834 $ 445,153
Schedule of depreciation and amortization expense	We reported depreciation and amortization expense (which included amortization of intangible assets) as follows: Years Ended March 31, (in thousands) 2024 2023 Cost of revenue $ 5,147 $ 5,213 Research and development 2,031 2,082 Selling, general and administrative 353 284 Total depreciation and amortization expense $ 7,531 $ 7,579
Schedule of Construction in Progress	Construction in progress consists primarily of the early phases of construction of our PHA plant in Bainbridge, Georgia (“Greenfield Facility”) as noted in the table below. (in thousands) March 31, December 31, Georgia $ 200,047 $ 199,342 New York 1,827 1,960 Kentucky 1,743 1,696 $ 203,617 $ 202,998

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets net	Intangible assets, net, consisted of the following: March 31, December 31, (in thousands) 2024 2023 Intangible assets, gross $ 96,276 $ 95,765 Less capitalized patent costs not yet subject to amortization ( 3,102 ) ( 2,838 ) Intangible assets subject to amortization, gross 93,174 92,927 Accumulated amortization ( 19,107 ) ( 17,975 ) Intangible assets subject to amortization, net 74,067 74,952 Total intangible assets, net $ 77,169 $ 77,790

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Accounts Payable and Accrued Liabilities [Abstract]
Schedule of accrued liabilities	The components of accrued liabilities were as follows: March 31, December 31, (in thousands) 2024 2023 Accrued interest $ 2,399 $ 440 Accrued legal, consulting and professional fees 1,408 839 Accrued taxes 912 552 Compensation and related expenses 508 1,692 Accrued utilities 341 350 Accrued rebates 288 233 Construction in progress accruals 51 191 Purchase accrual - 8 Other 577 421 Total accrued liabilities $ 6,484 $ 4,726

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2024
Disclosure Text Block [Abstract]
Schedule of operating lease costs	The following table sets forth the allocation of our operating lease costs. Three Months Ended March 31, (in thousands) 2024 2023 Cost of revenue $ 754 $ 581 Selling, general and administrative 33 137 Research and development 248 76 Total operating lease cost $ 1,035 $ 794

Warrant Liability (Tables)

Warrant Liability (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Measurement Inputs and Valuation Techniques [Abstract]
Schedule of Private & Common Warrants Liability	A rollforward of the Private Warrants liability is below. (in thousands) Balance at December 31, 2023 $ ( 5 ) Loss on remeasurement of private warrants ( 201 ) Balance at March 31, 2024 $ ( 206 ) A rollforward of the Common Warrants liability is below. (in thousands) Balance at March 25, 2024 $ ( 9,750 ) Gain on remeasurement of common warrants 300 Balance at March 31, 2024 $ ( 9,450 )

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Schedule of long-term debt	The components of long-term debt were as follows: March 31, December 31, (in thousands) 2024 2023 3.25 % Convertible Senior Notes $ 240,000 $ 240,000 Senior Secured Term Loan 130,000 130,000 New Market Tax Credit Transactions 45,700 45,700 Insurance Premium Finance Notes 671 1,243 Vehicle and Equipment Notes 296 327 Mortgage Notes 189 192 Total $ 416,856 $ 417,462 Less: Total unamortized debt issuance costs ( 31,840 ) ( 34,658 ) Less: Current maturities of long-term debt ( 787 ) ( 1,368 ) Total long-term debt $ 384,229 $ 381,436

Equity (Tables)

Equity (Tables)	3 Months Ended
	Mar. 31, 2024
Stockholders' Equity Note [Abstract]
Summary of Common Stock Activity	The following table summarizes the common stock activity for the three months ended March 31, 2024 and 2023, respectively. Three Months Ended March 31, 2024 2023 Balance, beginning of period 102,832,103 101,804,454 Issuance of common stock 11,408,818 133,922 Balance, end of period 114,240,921 101,938,376
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table summarizes the instruments excluded from the calculations of diluted shares outstanding because the effect of including them would have been anti-dilutive. Three Months Ended March 31,  2024  2023 Convertible Notes 22,250,040  22,250,040 Common Warrants 15,000,000 - Employee stock options 9,253,370  12,044,231 Private Warrants 3,914,525  3,914,525 Pre-Funded Warrants 3,750,000 - Senior Secured Term Loan Warrants 1,500,000 1,500,000 Restricted stock and RSUs 1,316,383 2,142,515 Performance stock 127,770 127,770 Legacy Danimer options 125,492  125,492 Total excluded instruments 57,237,580 42,104,573

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2024
Disaggregation of Revenue [Abstract]
Schedule of revenue information by major geographic area	Revenue by geographic areas is based on the location of the customer. The following table summarizes revenue information by major geographic area. Three Months Ended March 31, (in thousands) 2024 2023 Domestic $ 9,729 $ 10,274 Portugal 180 - Poland 155 77 Switzerland 91 - All other countries 69 1,575 Total revenues $ 10,224 $ 11,926

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based compensation expense	The following table sets forth the allocation of our stock-based compensation expense. Three Months Ended March 31, (in thousands) 2024 2023 Cost of revenue $ 3 $ 2 Selling, general and administrative 818 13,318 Research and development 145 1,623 Total stock-based compensation $ 966 $ 14,943
Schedule of option award on the date of grant using the Black-Scholes option	The following table summarizes our service-based restricted stock and RSU activity under our equity plan.   Number of Shares  Weighted Average Grant-Date Balance, December 31, 2023  271,550  $ 4.40 Granted 315,876 $ 1.49 Vested ( 34,364 ) $ 5.86 Balance, March 31, 2024 553,062 $ 1.82
Schedule of Performance-Based Restricted Stock Units	The following table summarizes pertinent facts related to PRSU grants, with threshold and target dollar and production capacity figures given in millions. Grant Date Grant-Date Fair Value # Cash-Settleable PRSUs # Share-Settleable PRSUs Metric Threshold Target 2/28/2023 $ 2.58 192,500 38,759 2025 PHA Revenue $ 177.0 $ 202.0 2/28/2023 $ 2.58 192,500 38,760 2025 Adjusted EBITDA $ 36.0 $ 44.0 3/31/2022 $ 5.86 131,909 15,075 2024 PHA Revenue $ 151.0 $ 189.0 3/31/2022 $ 5.86 131,909 15,075 2024 Adjusted EBITDA $ 9.2 $ 13.8 3/31/2022 $ 5.86 175,880 20,101 2024 Neat PHA capacity (lbs.) 68.0 81.0 824,698 127,770
Schedule of stock option activity under our equity plans	The following table summarizes share-settled stock option activity under our equity plans.   Number of Options  Weighted Average Exercise Price  Weighted Average Remaining Contractual Term (Years)  Aggregate Intrinsic Value Balance, December 31, 2023  9,257,704 $ 11.27 5.38 $ - Forfeited ( 4,334 ) Balance, March 31, 2024 9,253,370 $ 11.27 5.13 $ - Exercisable  8,118,263 $ 12.10 4.77 $ - Vested and expected to vest  9,253,370 $ 11.27 5.13 $ -

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Considerations [Abstract]
Schedule of ranges of values used and fair value determined	The following table sets forth the calculated fair values and the associated ranges of values we used for period remeasurement and for new grants in our Black-Scholes calculations for stock options, other than ESPP. March 31, Three Months Ended March 31, 2024 2024 2023 Share prices of our common stock $ 1.09 $ 1.09 $ 2.58 - $ 3.45 Expected volatilities 79.78 % 65.28 % - 100.92 % 49.08 % - 53.51 % Risk-free rates of return 4.21 % 4.13 % - 4.28 % 4.04 % - 4.40 % Expected option terms (years) 4.08 3.31 - 4.91 4.31 - 6.00 Calculated option values $ 0.23 $ 0.15 - $ 0.41 $ 0.20 - $ 2.04 The following table sets forth the fair values we calculated and the inputs we used in our Black-Scholes models for Private Warrants. March 31, December 31, 2024 2023 Share price of our common stock $ 1.09 $ 1.02 Expected volatility 95.80 % 56.66 % Risk-free rate of return 4.68 % 4.31 % Expected warrant term (years) 1.74 2.00 Fair value determined per warrant $ 0.05 $ 0.00 The following table sets forth the fair values we calculated and the inputs we used in our Black-Scholes models for Common Warrants. March 31, March 25, 2024 2024 Share price of our common stock $ 1.09 $ 1.08 Expected volatility 68.42 % 72.80 % Risk-free rate of return 4.12 % 4.15 % Expected warrant term (years) 5.49 5.50 Fair value determined per warrant $ 0.63 $ 0.65

Basis of Presentation (Addition

Basis of Presentation (Additional Information) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Description of Business and Basis of Presentation (Details) [Line Items]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Net loss and comprehensive (loss) income	$ 0
Unrestricted cash	$ 57,300

Business Combination (Additiona

Business Combination (Additional Information) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Business Combination (Details) [Line Items]
Net Income (Loss)	$ (27,263)	$ (36,639)
Right-of-use assets	$ 19,162		$ 19,160

Restricted Cash - Schedule of R

Restricted Cash - Schedule of Restricted Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Restricted Cash and Cash Equivalents Items [Line Items]
Cash and cash equivalents	$ 57,300
Total cash and cash equivalents and restricted cash	$ 71,580	$ 73,504	$ 133,675	$ 64,401

Inventories, net - Schedule of

Inventories, net - Schedule of inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Schedule of inventory [Abstract]
Raw materials	$ 11,843	$ 10,867
Work-in-progress	503	546
Finished goods and related items	13,643	13,857
Total inventories, net	$ 25,989	$ 25,270

Inventories, net (Additional In

Inventories, net (Additional Information) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Inventory, Net [Abstract]
Finished neat PHA included in finished goods	$ 8.1	$ 7.6
Inventory reserves fair value	$ 0.6

Property, Plant and Equipment_3

Property, Plant and Equipment, net (Details) - Schedule of Property, plant, and equipment, net - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 515,795	$ 514,715
Accumulated depreciation and amortization	(75,961)	(69,562)
Property, plant and equipment, net	$ 439,834	445,153
Land and improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	20 years
Property and equipment, gross	$ 92	92
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	110,540	110,531
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,191	2,191
Buildings [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	20 years
Buildings [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	40 years
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 190,556	190,111
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	20 years
Motor vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 903	903
Motor vehicles [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	7 years
Motor vehicles [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 474	474
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 7,422	7,415
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Construction-in-progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 203,617	$ 202,998

Property, Plant and Equipment_4

Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Total depreciation and amortization expense	$ 7,531	$ 7,579
Cost of revenue [Member]
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Total depreciation and amortization expense	5,147	5,213
Research & development [Member]
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Total depreciation and amortization expense	2,031	2,082
Selling, general, and administrative [Member]
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Total depreciation and amortization expense	$ 353	$ 284

Property, Plant and Equipment -

Property, Plant and Equipment - construction in prog (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment, Gross [Abstract]
Construction in Progress, Gross	$ 203,617	$ 202,998
Georgia
Property, Plant and Equipment, Gross [Abstract]
Construction in Progress, Gross	200,047	199,342
New York
Property, Plant and Equipment, Gross [Abstract]
Construction in Progress, Gross	1,827	1,960
Kentucky
Property, Plant and Equipment, Gross [Abstract]
Construction in Progress, Gross	$ 1,743	$ 1,696

Property, Plant and Equipment (

Property, Plant and Equipment (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property, plant, and equipment includes capitalized interest	$ 15	$ 15
Minimum [Member]
Property, Plant and Equipment [Line Items]
Engineering Cost	515
Maximum [Member]
Property, Plant and Equipment [Line Items]
Engineering Cost	$ 665

Intangible Assets (Additional I

Intangible Assets (Additional Information) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life	17 years 3 months 18 days
Amortization expense	$ 1.1	$ 1.1
Patents [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	20 years
Patents [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	10 years

Intangible Assets - Schedule of

Intangible Assets - Schedule of intangible assets net (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets, gross	$ 96,276	$ 95,765
Less capitalized patent costs not yet subject to amortization	(3,102)	(2,838)
Intangible assets subject to amortization, gross	93,174	92,927
Accumulated amortization	(19,107)	(17,975)
Intangible assets subject to amortization, net	74,067	74,952
Total intagible assets, net	$ 77,169	$ 77,790

Accrued Liabilities (Details) -

Accrued Liabilities (Details) - Schedule of accrued liabilities - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Schedule of accrued liabilities [Abstract]
Accrued interest	$ 2,399	$ 440
Accrued legal, consulting and professional fees	1,408	839
Accrued taxes	912	552
Compensation and related expenses	508	1,692
Accrued utilities	341	350
Accrued rebates	288	233
Construction in progress accruals	51	191
Purchase accrual	0	8
Other	577	421
Total accrued liabilities	$ 6,484	$ 4,726

New Markets Tax Credit Transact

New Markets Tax Credit Transactions (Details)	Mar. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Interest rate	8.24%	8.24%

Income Taxes (Additional Inform

Income Taxes (Additional Information) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income taxes	$ (2)	$ 90
Effective tax rates	0%	0.25%
Statutory rate	21%

Leases (Details) - Schedule of

Leases (Details) - Schedule of operating lease costs - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Total operating lease cost	$ 1,035	$ 794
Cost of revenue [Member]
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Total operating lease cost	754	581
Selling, general and administrative [Member]
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Total operating lease cost	33	137
Research and development [Member]
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Total operating lease cost	$ 248	$ 76

Warrant Liability (Details)

Warrant Liability (Details) - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 25, 2024	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Outstanding warrants (in Shares)	3,914,525		3,914,525
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 11.5		$ 11.5
Common Warrants
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.33
Warrants exercisable date	Sep. 25, 2024
Warrants issued for the purchase of common stock		15,000,000
Warrants expiration date	Sep. 25, 2029
Private Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants exercisable date	May 07, 2021
Warrants expiration date	Dec. 28, 2025

Warrant Liability - Summary of

Warrant Liability - Summary of Rollforward of Warrants Liability (Details) - USD ($) $ in Thousands		3 Months Ended
	Mar. 31, 2024	Mar. 31, 2024	Mar. 31, 2023
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Balance at March 25, 2024		$ 5
Gain on remeasurement of common warrants		$ (99)	$ 1,116
Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Liabilities	Liabilities
Balance at March 31, 2024	$ 9,656	$ 9,656
Private Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Balance at March 25, 2024		(5)
Gain on remeasurement of common warrants		(201)
Balance at March 31, 2024	(206)	(206)
Common Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Balance at March 25, 2024	(9,750)
Gain on remeasurement of common warrants	300
Balance at March 31, 2024	$ (9,450)	$ (9,450)

Debt (Details) - Schedule of lo

Debt (Details) - Schedule of long-term debt - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	$ 416,856	$ 417,462
Less: Total unamortized debt issuance costs	(31,840)	(34,658)
Less: Current maturities of long-term debt	(787)	(1,368)
Total long-term debt	384,229	381,436
Convertible Debt Note [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	240,000	240,000
Senior Secured Term Loan [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	130,000	130,000
New Market Tax Credit Transactions [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	45,700	45,700
Insurance Premium Finance Notes [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	671	1,243
Vehicle and Equipment Notes [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	296	327
Mortgage Notes [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	$ 189	$ 192

Debt Schedule of long-term debt

Debt Schedule of long-term debt - Parenthetical (Details)	Mar. 31, 2024	Dec. 31, 2023
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Interest rate	8.24%	8.24%
Convertible Debt Note [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Interest rate	3.25%

Debt (Details)

Debt (Details) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended
	Mar. 17, 2023	Dec. 21, 2021	Dec. 16, 2021	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Long-Term Debt (Details) [Line Items]
Convertible senior notes due year		2026
Accrued interest				$ 2,399		$ 440
Unrestricted cash on deposit				57,341		59,170
Leverage loans receivable				31,446		31,446
Minimum cash required				71,580	$ 133,675	$ 73,504	$ 64,401
Gain (loss) on remeasurement of warrants				$ (99)	$ 1,116
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 11.5		$ 11.5
Fair value of our Senior Secured Term Loan				$ 40,500
Shares issued, shares				11,408,818	133,922
Interest rate				8.24%		8.24%
Unrestricted cash				$ 57,300
Conversion price per share (in Dollars per share)								$ 10.79
Senior Notes [Member]
Long-Term Debt (Details) [Line Items]
Convertible senior notes issued		$ 240,000
Interest rate		3.25%
Senior Secured Term Loan [Member]
Long-Term Debt (Details) [Line Items]
Principal amount	$ 130,000
Gain (loss) on remeasurement of warrants	$ 500
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.5
Shares issued, shares	1,500,000
Interest rate	14.40%
Unrestricted cash	$ 12,500
Proceeds from loan	98,600
Note payable outstanding amount	$ 100,000
Convertible Debt Note [Member]
Long-Term Debt (Details) [Line Items]
Interest rate				3.25%
Mortgage Notes [Member]
Long-Term Debt (Details) [Line Items]
Debt instrument, maturity date, description				This note bears interest at 5.25% with a maturity date in May 2025.
Interest rate				5.25%
Minimum [Member] | Vehicle and Equipment Notes [Member]
Long-Term Debt (Details) [Line Items]
Interest rate				3.75%
Maximum [Member] | Vehicle and Equipment Notes [Member]
Long-Term Debt (Details) [Line Items]
Interest rate				6.99%
Capped Call Options [Member]
Long-Term Debt (Details) [Line Items]
Purchase of capped call options			$ 35,000
Capped calls expire date				Apr. 12, 2027

Debt - Schedule of future matur

Debt - Schedule of future maturities of long-term debt (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Schedule of future maturities of long-term debt [Abstract]
Total	$ 416,856	$ 417,462

Equity - Summary of Common Stoc

Equity - Summary of Common Stock Activity (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Balance, beginning of period	102,832,103	101,804,454
Issuance of common stock	11,408,818	133,922
Balance, end of period	114,240,921	101,938,376

Equity (Details)

Equity (Details) - USD ($) $ / shares in Units, $ in Millions						3 Months Ended	12 Months Ended
	Mar. 25, 2024	Mar. 20, 2024	Mar. 17, 2023	Sep. 07, 2022	Dec. 29, 2020	Mar. 31, 2024	Dec. 31, 2021	Dec. 31, 2016	Dec. 31, 2023
Stockholders' Equity (Details) [Line Items]
Preferred share, par value						$ 0.0001
Preferred stock, shares authorized						10,000,000
Preferred stock, shares issued						0			0
Preferred stock, shares outstanding						0			0
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 11.5			$ 11.5
Number of options outstanding						9,253,370			9,257,704
Legacy Danimer Options [Member]
Stockholders' Equity (Details) [Line Items]
Options issued								208,183
Weighted average exercise price per share								$ 30
Number of shares, exercised							153,763
Number of options outstanding						125,492			125,492
Exercisable and remained outstanding					30,493
Conversion of stock, shares issued					279,255
Weighted average exercise price, exercised					$ 3.28
Equity Distribution Agreement [Member]
Stockholders' Equity (Details) [Line Items]
Stock issued						590,661
Value of stock issued						$ 1.4
Stock issuance costs						1.4
Payments for commissions						0.1
Cash available for distributions						$ 48.6
Weighted average exercise price, exercised						$ 2.72
Registered Direct Offering [Member]
Stockholders' Equity (Details) [Line Items]
Sale of stock, share issued	11,250,000
Gross proceeds from registered direct offering	$ 15
Pre-Funded Warrants [Member]
Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.0001
Warrants expiration date						Mar. 26, 2029
Pre-Funded Warrants [Member] | Registered Direct Offering [Member]
Stockholders' Equity (Details) [Line Items]
Warrants issued for the purchase of common stock	3,750,000
Senior Loans [Member]
Stockholders' Equity (Details) [Line Items]
Sale of stock, price per share			$ 7.5
Conversion of stock, shares issued			1,500,000
Maximum [Member] | ATM Offering [Member] | Equity Distribution Agreement [Member]
Stockholders' Equity (Details) [Line Items]
Change in amount available for sale related to ATM offering		$ 100
Minimum [Member] | ATM Offering [Member] | Equity Distribution Agreement [Member]
Stockholders' Equity (Details) [Line Items]
Change in amount available for sale related to ATM offering		$ 50
Common Class A [Member] | Equity Distribution Agreement [Member]
Stockholders' Equity (Details) [Line Items]
Aggregate offering price, share issued				$ 100

Equity - Schedule of Antidiluti

Equity - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	57,237,580	42,104,573
Convertible Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	22,250,040	22,250,040
Common Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	15,000,000
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	9,253,370	12,044,231
Private Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,914,525	3,914,525
Pre-Funded Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,750,000	0
Senior Secured Term Loan Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,500,000	1,500,000
Restricted Shares and RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,316,383	2,142,515
Performance Shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	127,770	127,770
Legacy Danimer options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	125,492	125,492

Revenue (Additional Information

Revenue (Additional Information) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Long-Term Purchase Commitment [Line Items]
Contract assets recorded related to fulfillment costs	$ 1.3	$ 1.1
Research and Development Arrangement [Member]
Long-Term Purchase Commitment [Line Items]
Contract assets recorded related to fulfillment costs	3.9	3.7
Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent	$ 0.9	$ 0.7

Revenue - Change in Contract As

Revenue - Change in Contract Asset and Contract Liability Balance (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Beginning balance, Contract Liabilities	$ (1,000)
Ending Balance, Contract Liabilities	$ (1,154)

Revenue - Summary of Revenue In

Revenue - Summary of Revenue Information by Major Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Total revenue	$ 10,224	$ 11,926
Domestic
Disaggregation of Revenue [Line Items]
Total revenue	9,729	10,274
Portugal
Disaggregation of Revenue [Line Items]
Total revenue	180	0
Poland
Disaggregation of Revenue [Line Items]
Total revenue	155	77
Switzerland
Disaggregation of Revenue [Line Items]
Total revenue	91	0
All Other Countries
Disaggregation of Revenue [Line Items]
Total revenue	$ 69	$ 1,575

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2021	Dec. 31, 2023
Stock-Based Compensation (Details) [Line Items]
Issuance of common stock	11,408,818	133,922
Unrecognized compensation cost related to nonvested stock options grant (in Dollars)	$ 2,700
Weighted-average over period	10 months 24 days
Stock-based compensation expense	$ 200	$ 4,500
Long-term liability	$ 384,229			$ 381,436
Third anniversary [Member]
Stock-Based Compensation (Details) [Line Items]
Share prices of our common stock	$ 24.2
Performance Based Restricted Stock Units [Member]
Stock-Based Compensation (Details) [Line Items]
Vesting description	the vesting dates, which we anticipate will be in March 2025 and February 2026, for awards granted in 2022 and 2023, respectively. Our performance did not meet the required conditions for vesting for the PRSUs that were scheduled to vest in February 2024 and accordingly they expired unvested during the three months ended March 31, 2024. We are currently assuming 100% attainment of our 2025 metrics and 0% attainment of our 2024 metrics. All of the PRSUs granted in 2022 and 2023 remained outstanding at March 31, 2024.
Liability	$ 100
Recognized related compensation expense	$ 0	$ 300
Performance Based Restricted Stock Units [Member] | Maximum [Member]
Stock-Based Compensation (Details) [Line Items]
Vesting percentage	100%
Performance Based Restricted Stock Units [Member] | Minimum [Member]
Stock-Based Compensation (Details) [Line Items]
Vesting percentage	50%
Stock Option
Stock-Based Compensation (Details) [Line Items]
Weighted average grant-date fair value of options granted (in Dollars per share)		$ 1.17
Stock options		2,571,737
Number of Shares, Granted	0	204,254
Liability	$ 400
Long-term liability	$ 500			100
Market Based Restricted Shares [Member]
Stock-Based Compensation (Details) [Line Items]
Restricted stock shares	754,818
Number of Shares, Granted	1,517,840		1,517,840
Stock-based compensation expense		$ 4,700
Liability	$ 300			$ 300
Market Based Restricted Shares [Member] | Maximum [Member]
Stock-Based Compensation (Details) [Line Items]
Stock-based compensation expense	$ 400	$ 600
Cash Settled Options [Member]
Stock-Based Compensation (Details) [Line Items]
Number of Shares, Granted		1,050,000
2020 ESPP [Member]
Stock-Based Compensation (Details) [Line Items]
Issuance of common stock	136,530
Shares issued from inception	401,748
ESPP plan, percentage of stock discount	15%
Share-based compensation, authorized shares	2,571,737
2020 Incentive Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Share-based compensation, remained authorized for Issuance	4,519,719			4,823,519

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of stock based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount	$ 966	$ 14,943
Cost of revenue [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount	3	2
Selling, general and administrative [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount	818	13,318
Research and Development Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount	$ 145	$ 1,623

Share based compensation - Sche

Share based compensation - Schedule of Service-Based Restricted Stock And RSU Activity (Details)	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, Beginning | shares	9,257,704
Number of Shares, Ending | shares	9,253,370
Weighted Average Exercise Price, Beginning (in Dollars per share) | $ / shares	$ 11.27
Weighted Average Exercise Price, Ending (in Dollars per share) | $ / shares	$ 11.27
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, Beginning | shares	271,550
Number of Shares, Granted | shares	315,876
Number of Shares, Vested | shares	(34,364)
Number of Shares, Ending | shares	553,062
Weighted Average Exercise Price, Beginning (in Dollars per share) | $ / shares	$ 4.4
Weighted Average Exercise Price, Granted (in Dollars per share) | $ / shares	1.49
Weighted Average Exercise Price, Vested (in Dollars per share) | $ / shares	5.86
Weighted Average Exercise Price, Ending (in Dollars per share) | $ / shares	$ 1.82

Stock-based Compensation - Sc_2

Stock-based Compensation - Schedule of Performance-Based Restricted Stock Units (Details) - Performance Based Restricted Stock Units [Member] - USD ($) $ / shares in Units, $ in Millions			3 Months Ended
	Feb. 28, 2023	Mar. 31, 2022	Mar. 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period Performance based Restricted Stock Units Cash Setteable			824,698
Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 2.58	$ 5.86
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period Performance based Restricted Stock Units Cash Setteable	192,500	131,909
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period Performance based Restricted Stock Units Share Setteable	38,759	15,075	127,770
Share-Based Payment Arrangement, Tranche Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 2.58	$ 5.86
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period Performance based Restricted Stock Units Cash Setteable	192,500	131,909
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period Performance based Restricted Stock Units Share Setteable	38,760	15,075
Share-Based Payment Arrangement, Tranche Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 5.86
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period Performance based Restricted Stock Units Cash Setteable		175,880
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period Performance based Restricted Stock Units Share Setteable		20,101
PHA Revenue [Member] | Two Thousand Twenty Five PHA [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	$ 202
PHA Revenue [Member] | Two Thousand Twenty Five PHA [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	177
PHA Revenue [Member] | Two Thousand Twenty Four [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Revenue from Contract with Customer, Including Assessed Tax		$ 189
PHA Revenue [Member] | Two Thousand Twenty Four [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Revenue from Contract with Customer, Including Assessed Tax		151
Adjusted EBITDA [Member] | Two Thousand Twenty Five PHA [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	44
Adjusted EBITDA [Member] | Two Thousand Twenty Five PHA [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	$ 36
Adjusted EBITDA [Member] | Two Thousand Twenty Four [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Revenue from Contract with Customer, Including Assessed Tax		13.8
Adjusted EBITDA [Member] | Two Thousand Twenty Four [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Revenue from Contract with Customer, Including Assessed Tax		9.2
2024 Neat PHA capacity (lbs.) [Member] | Two Thousand Twenty Four [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Revenue from Contract with Customer, Including Assessed Tax		81
2024 Neat PHA capacity (lbs.) [Member] | Two Thousand Twenty Four [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Revenue from Contract with Customer, Including Assessed Tax		$ 68

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of stock option activity under our equity plans - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, Beginning	9,257,704
Number of Shares, Forfeited	(4,334)
Number of Shares, Ending	9,253,370	9,257,704
Number of Shares, Exercisable	8,118,263
Number of Shares, Vested and expected to vest	9,253,370
Weighted Average Exercise Price, Beginning (in Dollars per share)	$ 11.27
Weighted Average Exercise Price, Ending (in Dollars per share)	11.27	$ 11.27
Weighted Average Exercise Price, Exercisable (in Dollars per share)	12.1
Weighted Average Exercise Price, Vested and expected to vest (in Dollars per share)	$ 11.27
Weighted Average Remaining Contractual Term (Years)		5 years 4 months 17 days
Weighted Average Remaining Contractual Term (Years)	5 years 1 month 17 days
Weighted Average Remaining Contractual Term (Years), Exercisable	4 years 9 months 7 days
Weighted Average Remaining Contractual Term (Years), Vested and expected to vest	5 years 1 month 17 days
Aggregate Intrinsic Value, Beginning (in Dollars)	$ 0
Aggregate Intrinsic Value, Ending (in Dollars)	0	$ 0
Aggregate Intrinsic Value, Exercisable (in Dollars)	0
Aggregate Intrinsic Value, Vested and expected to vest (in Dollars)	$ 0
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, Beginning	271,550
Number of Shares, Ending	553,062	271,550
Weighted Average Exercise Price, Beginning (in Dollars per share)	$ 4.4
Weighted Average Exercise Price, Ending (in Dollars per share)	$ 1.82	$ 4.4

Fair Value Considerations (Addi

Fair Value Considerations (Additional Information) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price per (in Dollars per share)	$ 11.5	$ 11.5
Fair value of our Senior Secured Term Loan	$ 40.5
Fair value of convertible debt	$ 17.8
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Remaining stock, closing price	$ 1.09

Fair Value Considerations - Sch

Fair Value Considerations - Schedule of ranges of values used and fair value determined (Details) - Black-Scholes [Member] - $ / shares		3 Months Ended		12 Months Ended
	Mar. 25, 2024	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share prices of our common stock		$ 1.09
Expected volatility		79.78%
Expected Volatility Rate, Maximum		100.92%	53.51%
Expected Volatility Rate, Minimum		65.28%	49.08%
Risk-free rate of return		4.21%
Risk Free Interest Rate, Maximum		4.28%	4.40%
Risk Free Interest Rate, Minimum		4.13%	4.04%
Expected term (years)		4 years 29 days
Stock Option [Member] | Danimer Black Sholes [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Calculated option values, Minimum		$ 0.23
Stock Option [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share prices of our common stock			$ 3.45
Expected term (years)		4 years 10 months 28 days	6 years
Stock Option [Member] | Maximum [Member] | Danimer Black Sholes [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Calculated option values, Maximum		$ 0.41	$ 2.04
Stock Option [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share prices of our common stock			$ 2.58
Expected term (years)		3 years 3 months 21 days	4 years 3 months 21 days
Stock Option [Member] | Minimum [Member] | Danimer Black Sholes [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Calculated option values, Minimum		$ 0.15	$ 0.2
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share prices of our common stock	$ 1.08	$ 1.09
Expected volatility	72.80%	68.42%
Risk-free rate of return	4.15%	4.12%
Expected term (years)	5 years 6 months	5 years 5 months 26 days
Fair value determined per warrant	$ 0.65	$ 0.63
Private Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share prices of our common stock		$ 1.09		$ 1.02
Expected volatility		95.80%		56.66%
Risk-free rate of return		4.68%		4.31%
Expected term (years)		1 year 8 months 26 days		2 years
Fair value determined per warrant		$ 0.05		$ 0

Commitments and Contingencies A

Commitments and Contingencies Additional Information (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($) $ / shares
Commitments and Contingencies Disclosure [Abstract]
Royalty per share (in Pounds per share) | $ / shares	$ 0.05
Weight of PHA Sold (in Pounds) | $	$ 500
Decrease royalty per share (in Pounds per share) | $ / shares	$ 0.025
Loss on forfeiture | $	$ 0.5

Subsequent Events (Additional I

Subsequent Events (Additional Information) (Details) - Subsequent Event [Member] - Revolving Credit Agreement [Member] $ in Millions	Apr. 19, 2024 USD ($)
Subsequent Event [Line Items]
Borrowings	$ 20
Revolving commitment available for borrowing	$ 18.5
Revolving credit agreement interest payment term	Amounts borrowed under the Revolving Credit Agreement accrue interest at an annual rate equal to the Secured Overnight Financing Rate plus 7%, and any unborrowed Revolving Commitment accrues an unused facility fee at an annual rate of 0.5%, each payable monthly. The Revolving Credit Agreement matures on April 19, 2027; however, certain provisions exist that can accelerate the maturity date
Revolving credit agreement interest on unused facility	0.50%
Revolving credit agreement interest payment frequency	monthly
Revolving credit agreement maturity date	Apr. 19, 2027
Secured Overnight Financing Rate Sofr [Member]
Subsequent Event [Line Items]
Revolving credit agreement interest rate	7%
Maximum [Member]
Subsequent Event [Line Items]
Increase in the Revolving Commitment	$ 5
Minimum [Member]
Subsequent Event [Line Items]
Increase in the Revolving Commitment	$ 2.5